The 2022 AHA/ACC/HFSA gGidelines provide a Class IA recommendation for the addition of hydralazine and isosorbide dinitrate to reduce morbidity and mortality in African American patients with NYHA class II-IV HFrEF otherwise on optimal medical therapy, while noting that this therapy has not been ...